Ewing sarcoma in an infant and review of the literature

Bedük-Esen, Çağlayan Selenge; Gültekin, M.; Aydın, Güzide Burça; Akyüz, Canan; Oğuz, Kader K.; Orhan, Dıclehan; Cengiz, Mustafa; Gurkaynak, M.; Yıldız, Ferah

doi:10.24953/turkjped.2019.05.016

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of relapses occur within the first 2 years of diagnosis, with shorter periods to recurrence predicting worse long-term survival 19. There is evidence that infants with congenital EWS have increased risk of early death, but whether this is due to toxicity of chemotherapy or disease progression is unclear 20. Our patient completed all 14 cycles of chemotherapy and is in outpatient surveillance.…”

Section: Discussionmentioning

confidence: 89%

“…19 There is evidence that infants with congenital EWS have increased risk of early death, but whether this is due to toxicity of chemotherapy or disease progression is unclear. 20 Our patient completed all 14 cycles of chemotherapy and is in outpatient surveillance. Her follow-up consisted of endof-treatment CT chest and MRI head/neck scans 1 month after discharge from the hospital.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Congenital Ewing Sarcoma Presenting as a Rapidly Growing Neck Mass in a Newborn

Pearl

Hibbs

et al. 2022

Advances in Neonatal Care

View full text Add to dashboard Cite

Background: Ewing sarcoma (EWS) is an aggressive soft-tissue and bone malignancy. Congenital EWS is extremely rare, and its presenting features can be unique from that of EWS occurring in older children. Clinical Findings: A full-term female infant with a neck mass present at birth was admitted to a level I nursery with an otherwise well appearance and normal vital signs. After consultation with a neonatologist, she was transferred to a neonatal intensive care unit where she developed sudden respiratory collapse from rapid growth of the mass causing airway obstruction, leading to emergent intubation. Ultrasound and MRI scans of the neck mass demonstrated cystic and vascular components, and a timely biopsy revealed small round blue cells with diffuse CD99 expression and chromosomal translocation 11;22. Primary Diagnosis: Ewing sarcoma. Interventions: An accelerated workup for EWS was done due to the patient's critical status. On day of life (DOL) 8, she was started on treatment of EWS as per the current standard-of-care AEWS0031. On DOL 24, she underwent tracheostomy placement. Outcomes: The patient completed 14 total cycles of chemotherapy and is more than 12 months old. Her tracheostomy was decannulated at 6 months of age. Practice Recommendations: The rarity of EWS in neonates and its presentation as a neck mass make this disease difficult to recognize unless clinicians have a high index of suspicion. The aims of this case report are to increase awareness of malignancy as a potential cause of neck masses in neonates and to prompt nurses and physicians to prepare for airway stabilization at appropriate levels of care if a neck mass is present at birth.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 93%

Congenital Ewing Sarcoma Presenting as a Rapidly Growing Neck Mass in a Newborn

Pearl

Hibbs

et al. 2022

Advances in Neonatal Care

View full text Add to dashboard Cite

show abstract

“…It is common in adolescents, and the incidence rate accounts for 10 to 15% of orthopedic tumors [2]. The peak incidence occurs at the age of 15, and the incidence rate in males is higher than in females, with a ratio of 3:2 [3]. Although Ewing sarcoma accounts for only 1% of human malignant tumors, it is extremely aggressive and can rapidly metastasize to the lung and other tissues.…”

Section: Introductionmentioning

confidence: 99%

“…The survival rate of patients is approximately 70% after five years and decreases sharply to 30% after 10 years. Tumor metastasis at the time of diagnosis further reduces the survival rate after five years to only 25% [3]. The poor survival rate of Ewing sarcoma has since gained awareness.…”

Section: Introductionmentioning

confidence: 99%

Bibliometric analysis of Ewing sarcoma from 1993 to 2022

2023

View full text Add to dashboard Cite

Background Ewing sarcoma has attracted more attention in recent years but has yet to be bibliometrically analyzed. Hence, this study investigated the trend of Ewing sarcoma over the past 30 years with bibliometric analysis. Methods Original publications related to Ewing sarcoma were obtained from the Science Citation Index Extension (SCI-E), Social Sciences Citation Index (SSCI), and Web of Science Core Collection (WoSCC) between 1993 and 2022. CiteSpace and VOSviewer were used to extract the countries/regions, institutions, authors, journals, references, and keywords involved in this topic to identify and analyze the research hotspots and trends in this field. Results Over the past 30 years (especially in the past five years), the number of articles published on Ewing sarcoma continued to increase, and the most published country was the United States of America (USA). High-frequency keywords included "Ewing sarcoma", "tumor", "family", "bone", "chemotherapy", "expression", "primitive neuroectodermal tumor", "prognostic factors", "children", and "survival rate". According to the analysis of keyword saliency of Ewing sarcoma, we found that "chromosome translocation", "intergroup", "sarcoma", "genomic landscape", and "children oncology group" were emerging research hotspots. The timeline of the cluster map of co-cited literature indicated that the treatment of Ewing sarcoma emerged as a research hotspot. Conclusion Researchers' understanding of Ewing sarcoma has improved dramatically over the past 30 years. At present, the research hotspots of Ewing sarcoma mainly focus on the aspects of "chromosome translocation", "intergroup", and "sarcoma". In addition, the timeline of the cluster map of co-cited literature indicated the emergence of the treatment of Ewing sarcoma as a research hotspot.

show abstract